⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 1, 2024ImmunoTargets and TherapyOpen Access

Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study

Murong Wang Qunfang Zhou Hui Li Mingyu Liu Ruixia Li Wei Wang Xiaohui Wang Jinhua Huang Feng Duan

View Full Paper

Ask AI

Bookmark

Share

Abstract

The outcome between Lenvatinib plus programmed cell death protein-1 (PD-1) inhibitor and Lenvatinib in HCC beyond oligometastasis was unclear. In this multicenter, we compared the prognosis of Lenvatinib plus PD-1 inhibitor with Lenvatinib in HCC beyond oligometastasis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e59f9eb6db643587539978 https://doi.org/10.2147/itt.s477972

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Hepatic arterial infusion chemotherapy plus lenvatinib with or without PD-1 inhibition for unresectable hepatocellular carcinoma: a retrospective cohort studyCohort Study · 2026
2Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study2024 · 9 citations
3Hepatic arterial infusion chemotherapy plus lenvatinib and programmed death receptor 1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombosis: a prospective controlled studyOriginal Research · 2026
4Efficacy of Lenvatinib Combined with PD-1 Inhibitor versus Sorafenib and PD-1 Inhibitor with or Without TACE for Hepatocellular Carcinoma with Extrahepatic Metastasis2024 · 3 citations
5Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis2024 · 2 citations